International Stem Cell Corp. specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. ISCO has a strong patent portfolio offering clean intellectual property and was the first to develop and perfect a new class of human stem cells created from unfertilized human eggs through the company’s patented process.
After highlighting his own extensive background as a scientist in the life science industry, Dr. Craw provides information on the company’s CEO Professor Andrew Semechkin, a Russian Academy of Science member and internationally recognized scientist and business man.
Dr. Craw then explains considerable advances in the company’s Parkinson’s disease program, for which ISCO has carried out several stem cell-based experiments and recently concluded its first pilot primate study with favorable results.
“On the research and development side, the most significant achievements we’ve made this year are really in our Parkinson’s disease program …” says Dr. Craw. “This study was very very important for us to demonstrate that the symptoms of Parkinson’s can be alleviated using a stem cell therapy and it’s a precursor to any human studies that we would want to carry out.”
ISCO in mid-2104 plans to submit to the U.S. FDA an investigational new drug (IND) application, and recently engaged Duke University as a partner to carry out the phase I clinical study of Parkinson’s disease in human subjects.
Dr. Craw gives an in-depth explanation of the company’s core technology, demonstrating how the company’s stem cells are clinically superior in their ability to differentiate into other cells to treat millions of individuals without restriction, and how they bypass ethical controversy of embryonic stem cells.
“What we have at International Stem Cells is a proprietary stem cell platform that is unique and differentiated and actually offers substantial benefits over other stem cell platforms that are out there,” he says.
Dr. Craw also offers an outlook on the company’s goals for the remainder of 2013, including:
• Grow full-year 2013 revenue by approximately 20 percent over 2012
• Launching new products through subsidiary companies
• Filing submission with the FDA to request a pre-IND meeting to discuss a plan for the clinical trials
• Publishing results of its primate model study in peer-reviewed scientific journals
Looking beyond 2013, the company anticipates starting its phase 1 clinical trials in the middle of next year, representing a significant achievement for ISCO and individuals with the disease.
“That will be a very important milestone not just for the company but for everyone who suffers from this debilitating disease. We’ll be the first company in the world that will be taking a stem-cell based product from a pluripotent stem cell platform and using it to treat people with this disease,” Dr. Craw says in conclusion.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment